Article
Cardiac & Cardiovascular Systems
Alex Horby Christensen, Pyotr G. Platonov, Anneli Svensson, Henrik K. Jensen, Christine Rootwelt-Norberg, Pia Dahlberg, Trine Madsen, Tanja Charlotte Frederiksen, Tiina Helio, Kristina H. Haugaa, Henning Bundgaard, Jesper H. Svendsen
Summary: This study describes the complications associated with implantable cardioverter-defibrillators (ICD) treatment in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). The results show that during long-term follow-up, approximately 41% of patients experienced potentially life-saving ICD therapy, while 27% had complications requiring surgery, mainly lead-related complications.
Article
Cardiac & Cardiovascular Systems
Estelle Gandjbakhch, Mikael Laredo, Antonio Berruezo, Jean-Basptiste Gourraud, Jean-Marc Sellal, Raphael Martins, Frederic Sacher, Laurent Pison, Etienne Pruvot, Beatriz Jauregui, Antonio Frontera, Saurabh Kumar, Tom Wong, Paolo DellaBella, Philippe Maury
Summary: In patients with ARVC, well-tolerated MVT without a back-up ICD did not lead to fatal arrhythmic event after RCA despite VT recurrences in some. Our data suggest that RCA may be an alternative to ICD in selected ARVC patients.
Article
Cardiac & Cardiovascular Systems
Paloma Jorda, Laurens P. Bosman, Alessio Gasperetti, Andrea Mazzanti, Jean-Baptiste Gourraud, Brianna Davies, Tanja Charlotte Frederiksen, Zoraida Moreno Weidmann, Andrea Di Marco, Jason D. Roberts, Ciorsti MacIntyre, Colette Seifer, Antoine Deliniere, Wael Alqarawi, Deni Kukavica, Damien Minois, Alessandro Trancuccio, Marine Arnaud, Mattia Targetti, Annamaria Martino, Giada Oliviero, Daniel C. Pipilas, Corrado Carbucicchio, Paolo Compagnucci, Antonio Dello Russo, Iacopo Olivotto, Leonardo Calo, Steven A. Lubitz, Michael J. Cutler, Philippe Chevalier, Elena Arbelo, Silvia Giuliana Priori, Jeffrey S. Healey, Hugh Calkins, Michela Casella, Henrik Kjaerulf Jensen, Claudio Tondo, Rafik Tadros, Cynthia A. James, Andrew D. Krahn, Julia Cadrin-Tourigny
Summary: This study validated a 5-year risk prediction model for ARVC patients, demonstrating its superior performance in guiding ICD implantation decisions compared to other published guidelines and consensus statements. The findings support the use of this model for shared decision making in the primary prevention of SCD in ARVC patients.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Laurens P. Bosman, Claire L. Nielsen Gerlach, Julia Cadrin-Tourigny, Gabriela Orgeron, Crystal Tichnell, Brittney Murray, Mimount Bourfiss, Jeroen F. van der Heijden, Sing-Chien Yap, Katja Zeppenfeld, Maarten P. van den Berg, Arthur A. M. Wilde, Folkert W. Asselbergs, Hariskrishna Tandri, Hugh Calkins, J. Peter van Tintelen, Cynthia A. James, Anneline S. J. M. te Riele
Summary: This study aimed to validate and compare the performance of four different algorithms in ARVC patients. The ITFC and mITFC algorithms showed higher sensitivity and protection rates, while the AHA and HRS algorithms reduced unnecessary ICD placements.
Article
Cardiac & Cardiovascular Systems
Shohreh Honarbakhsh, Alexander Protonotarios, Christopher Monkhouse, Ross J. Hunter, Perry M. Elliott, Pier D. Lambiase
Summary: The aim of this study was to characterize VA events in ARVC patients and investigate if certain parameters can predict specific VA events. The results showed that ARVC patients had a high rate of VA events, with most of them being VT resulting in ICD shocks. Severely impaired RV function was an independent predictor of VT resulting in ATP.
Article
Cardiac & Cardiovascular Systems
Richard T. Carrick, Anneline S. J. M. te Riele, Alessio Gasperetti, Laurens Bosman, Steven A. Muller, Catherine Pendleton, Crystal Tichnell, Brittney Murray, Sing-Chien Yap, Maarten P. van den Berg, Arthur Wilde, Katja Zeppenfeld, Allison Hays, Stefan L. Zimmerman, Harikrishna Tandri, Julia Cadrin-Tourigny, Peter van Tintelen, Hugh Calkins, Cynthia A. James, Katherine C. Wu
Summary: Risk factors for VA in ARVC are dynamic and overall risk for incident sustained VA decreases during follow-up. Up-to-date risk factor assessment improves VA risk stratification.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
(2022)
Article
Medicine, General & Internal
Nixiao Zhang, Chuangshi Wang, Alessio Gasperetti, Yanyan Song, Hongxia Niu, Min Gu, Firat Duru, Liang Chen, Shu Zhang, Wei Hua
Summary: The study validated the good fitness of the novel risk-prediction model in predicting arrhythmic risk in Asian ARVC patients for primary prevention, and for secondary prevention patients after recalibration of the baseline risk. The performance of the prediction model in secondary prevention patients was improved after recalibration.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Federico Migliore, Raimondo Pittorru, Manuel De Lazzari, Alberto Cipriani, Barbara Bauce, Martina Perazzolo Marra, Enrico Giacomin, Pietro Bernardo Dall'Aglio, Stefano Accinelli, Sabino Iliceto, Domenico Corrado
Summary: This study evaluated the long-term outcome of patients with arrhyth-mogenic cardiomyopathy (ACM) who underwent third-generation subcutaneous implantable cardioverter defibrillator (S-ICD) implantation with the intermuscular (IM) two-incision technique. The findings showed that although the third-generation S-ICD with the IM two-incision technique appeared to have a low risk of complications and inappropriate shocks (IS) due to cardiac oversensing, the risk of IS due to myopotential mainly during effort should be considered.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Alwin B. P. Noordman, Alexander H. Maass, Hessel Groenveld, Bart A. Mulder, Michiel Rienstra, Yuri Blaauw
Summary: This study showed that myocardial scar characterization based on cardiac magnetic resonance imaging can improve risk stratification for ventricular arrhythmia occurrence in patients with ischemic cardiomyopathy who received an Implantable Cardioverter-Defibrillator (ICD). The analysis revealed that total scar mass and border zone mass independently predicted appropriate ICD therapy, suggesting the importance of myocardial scar assessment in determining the risk of ventricular arrhythmias in this patient population.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Biology
Fabrizio Guarracini, Alberto Preda, Eleonora Bonvicini, Alessio Coser, Marta Martin, Silvia Quintarelli, Lorenzo Gigli, Matteo Baroni, Sara Vargiu, Marisa Varrenti, Giovanni Battista Forleo, Patrizio Mazzone, Roberto Bonmassari, Massimiliano Marini, Andrea Droghetti
Summary: The difference between subcutaneous implantable cardioverter defibrillators (S-ICDs) and transvenous ICDs (TV-ICDs) lies in the extra-thoracic implantation of S-ICDs, without endovascular components. S-ICDs have been rapidly adopted due to their improved safety profile, especially among younger patients. Although S-ICDs show comparable efficacy, reliability, and safety outcomes to TV-ICDs, technical issues limit their employment, making them an alternative rather than a mainstream option.
Article
Cardiac & Cardiovascular Systems
Julia Cadrin-Tourigny, Laurens P. Bosman, Anna Nozza, Weijia Wang, Rafik Tadros, Aditya Bhonsale, Mimount Bourfiss, Annik Fortier, Oyvind H. Lie, Ardan M. Saguner, Anneli Svensson, Antoine Andorin, Crystal Tichnell, Brittney Murray, Katja Zeppenfeld, Maarten P. van den Berg, Folkert W. Asselbergs, Arthur A. M. Wilde, Andrew D. Krahn, Mario Talajic, Lena Rivard, Stephen Chelko, Stefan L. Zimmerman, Ihab R. Kamel, Jane E. Crosson, Daniel P. Judge, Sing-Chien Yap, Jeroen F. van der Heijden, Harikrishna Tandri, Jan D. H. Jongbloed, Marie-Claude Guertin, J. Peter van Tintelen, Pyotr G. Platonov, Firat Duru, Kristina H. Haugaa, Paul Khairy, Richard N. W. Hauer, Hugh Calkins, Anneline S. J. M. te Riele, Cynthia A. James
Summary: We developed a prediction model for incident VA/SCD in ARVC patients using readily available clinical parameters, which accurately distinguished patients with and without events and showed superior clinical benefit compared to current ICD placement algorithms.
EUROPEAN HEART JOURNAL
(2022)
Review
Cardiac & Cardiovascular Systems
Andrew D. Krahn, Arthur A. M. Wilde, Hugh Calkins, Andre La Gerche, Julia Cadrin-Tourigny, Jason D. Roberts, Hui-Chen Han
Summary: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a condition characterized by right ventricular fibrofatty infiltration and arrhythmias. The diagnosis relies on the fulfillment of task force criteria incorporating electrophysiological parameters, cardiac imaging findings, genetic factors, and histopathologic features. Risk stratification of ARVC aims to identify individuals at higher risk of sudden cardiac death or sustained ventricular tachycardia. Current management options for ARVC include exercise restriction, medication therapy, consideration for implantable cardioverter-defibrillator insertion, and catheter ablation.
JACC-CLINICAL ELECTROPHYSIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Arwa Younis, Ilan Goldenberg, Shamroz Farooq, Hagai Yavin, James Daubert, Merritt Raitt, Alexander Mazur, David T. Huang, Brent L. Mitchell, Mayer R. Rashtian, Stephen Winters, Margot Vloka, Mehmet Aktas, Matthew A. Bernabei, Christopher A. Beck, Scott McNitt, Wojciech Zareba
Summary: The study analyzed data from the RAID trial and found that ranolazine treatment reduced VTA burden in patients at high risk, particularly in those without concomitant AAD therapy, cardiac resynchronization therapy (CRT)-treated patients, and patients without atrial fibrillation (AF). However, the addition of ranolazine did not affect VTA burden in patients already on AADs or those with AF.
JACC-CLINICAL ELECTROPHYSIOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Michal Miroslaw Farkowski, Michal Karlinski, Mariusz Pytkowski, Carlo de Asmundis, Michal Lewandowski, Giacomo Mugnai, Giulio Conte, Eloi Marijon, Ante Anic, Serge Boveda, Rui Providencia
Summary: This study systematically reviewed the effectiveness and safety of oral mexiletine in adult patients with structural heart disease and implantable cardioverter defibrillators for recurrent ventricular arrhythmia. The results showed that mexiletine reduced the number of ICD therapies, especially in patients where catheter ablation was not successful or contraindicated. However, in patients with ischemic cardiomyopathy, mexiletine seemed to be less effective than catheter ablation. The main side effects of mexiletine were related to gastrointestinal and neurological systems.
Article
Cardiac & Cardiovascular Systems
Marit Kristine Smedsrud, Monica Chivulescu, Marianne Inngjerdingen Forsa, Isotta Castrini, Eivind Westrum Aabel, Christine Rootwelt-Norberg, Martin Proven Bogsrud, Thor Edvardsen, Nina Eide Hasselberg, Andreas Fruh, Kristina Hermann Haugaa
Summary: The study aimed to investigate the incidence of severe cardiac events in paediatric arrhythmogenic right ventricular cardiomyopathy (ARVC) patients and the ARVC penetrance in paediatric relatives. The results showed a high incidence of severe cardiac events in paediatric ARVC cohort, with half occurring in children aged 12 or below. Additionally, the ARVC penetrance in genotype positive paediatric relatives was 18%.
EUROPEAN HEART JOURNAL
(2022)